PMID- 16545870
OWN - NLM
STAT- MEDLINE
DCOM- 20071012
LR  - 20151119
IS  - 0145-2126 (Print)
IS  - 0145-2126 (Linking)
VI  - 31
IP  - 2
DP  - 2007 Feb
TI  - Clinical relevance of soluble HLA-I and beta2-microglobulin levels in 
      non-Hodgkin's lymphoma and Hodgkin's disease.
PG  - 139-45
AB  - Plasma levels of beta-2 microglobulin (beta2M), a subunit of the human leukocyte 
      antigen-class I (HLA-I) molecule, correlate negatively with outcome in 
      non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). We examined the clinical 
      relevance of soluble HLA-I (sHLA-I) levels in NHL and HD. Sera from consecutive 
      NHL (n=65) and HD (n=37) patients were analyzed in a blinded manner. NHL and HD 
      patients had significantly higher levels of sHLA-1 and beta2M than control 
      subjects. In NHL patients, sHLA-I levels correlated with clinical behavior in a 
      fashion similar to that of beta2M. However, multivariate analysis incorporating 
      beta2M, sHLA-I, and international prognostic index (IPI) indicated that NHL 
      patients with elevated (>312.6mug/100mL) sHLA-I levels had significantly shorter 
      survival, independent of IPI score as well as beta2M. In HD patients, beta2M but 
      not sHLA-I levels were associated with clinical behavior. These findings not only 
      establish the role of sHLA-I as an independent tumor marker in NHL that can be 
      used to stratify patients, but also suggest that beta2M and sHLA-I may reflect 
      different biological processes in HD and NHL. Further studies are needed to 
      assess whether the immunomodulatory properties of sHLA-I may be responsible for 
      its divergence from beta2M as an indicator of clinical behavior in HD.
FAU - Albitar, Maher
AU  - Albitar M
AD  - Quest Diagnostics Nichols Institute, 33608 Ortega Highway, Rm#108B, San Juan 
      Capistrano, CA 92690-6130, United States. maher.x.albitar@questdiagnostics.com
FAU - Vose, Julie M
AU  - Vose JM
FAU - Johnson, Marcella M
AU  - Johnson MM
FAU - Do, Kim-Ann
AU  - Do KA
FAU - Day, Amanda
AU  - Day A
FAU - Jilani, Iman
AU  - Jilani I
FAU - Kantarjian, Hagop
AU  - Kantarjian H
FAU - Keating, Michael
AU  - Keating M
FAU - O'Brien, Susan M
AU  - O'Brien SM
FAU - Verstovsek, Srdan
AU  - Verstovsek S
FAU - Armitage, James O
AU  - Armitage JO
FAU - Giles, Francis J
AU  - Giles FJ
LA  - eng
PT  - Journal Article
DEP - 20060320
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA Antigens)
RN  - 0 (beta 2-Microglobulin)
SB  - IM
CIN - Leuk Res. 2007 Feb;31(2):121-5. PMID: 16860865
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Female
MH  - HLA Antigens/*blood
MH  - Hodgkin Disease/*blood/therapy
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/*blood/therapy
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Solubility
MH  - Survival Rate
MH  - Time Factors
MH  - Treatment Outcome
MH  - beta 2-Microglobulin/*blood
EDAT- 2006/03/21 09:00
MHDA- 2007/10/13 09:00
CRDT- 2006/03/21 09:00
PHST- 2005/07/15 00:00 [received]
PHST- 2005/12/22 00:00 [revised]
PHST- 2006/02/01 00:00 [accepted]
PHST- 2006/03/21 09:00 [pubmed]
PHST- 2007/10/13 09:00 [medline]
PHST- 2006/03/21 09:00 [entrez]
AID - S0145-2126(06)00055-5 [pii]
AID - 10.1016/j.leukres.2006.02.013 [doi]
PST - ppublish
SO  - Leuk Res. 2007 Feb;31(2):139-45. doi: 10.1016/j.leukres.2006.02.013. Epub 2006 
      Mar 20.